Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Prothena Corporation plc (NASDAQ:PRTA) has been making waves in the biotechnology industry with its cutting-edge research and development in the field of protein dysregulation. The company, which focuses on developing novel therapies for serious diseases, has recently announced that it will be reporting its fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets.

This news has generated a lot of excitement among investors and industry experts, who are eagerly waiting to see the progress of Prothena’s robust pipeline of investigational therapeutics. With its strong expertise in protein dysregulation, Prothena has been able to develop a diverse portfolio of potential treatments for a wide range of diseases.

Prothena’s CEO, Dr. Gene Kinney, expressed his enthusiasm for the upcoming financial results announcement, stating, “We are excited to share our progress and achievements with the investment community. Our team has been working tirelessly to advance our pipeline and we are confident that our efforts will continue to yield positive results.”

Prothena’s pipeline includes multiple late-stage clinical trials, with its lead candidate PRX004 in Phase 3 development for the treatment of ATTR amyloidosis, a rare and debilitating disease. The company also has several other candidates in various stages of clinical trials for diseases such as Parkinson’s, Alzheimer’s, and inflammatory diseases.

The company’s financial results announcement will be followed by a conference call and webcast at 4:30 p.m. ET that same day. During the call, Prothena’s management team will provide a detailed overview of the company’s financial performance for the fourth quarter and full year of 2025, as well as updates on its pipeline and future plans.

Investors and analysts are eagerly anticipating the financial results, as Prothena has consistently shown strong financial performance in the past. In its most recent quarter, the company reported a 34% increase in revenue compared to the same period in the previous year, driven by milestone payments from its collaboration with Roche.

Prothena’s success can also be attributed to its strong partnerships with leading pharmaceutical companies such as Roche, Celgene, and AbbVie. These collaborations not only provide the company with additional resources and expertise but also validate the potential of its innovative therapies.

The company’s dedication to advancing scientific research and its commitment to improving the lives of patients has garnered recognition and support from the medical community. In 2025, Prothena was awarded the prestigious Prix Galien USA Award for Best Biotechnology Product for its lead candidate, PRX004.

With its strong financial performance, promising pipeline, and recognition from the industry, Prothena is well-positioned for future success. The company’s focus on protein dysregulation puts it at the forefront of the biotechnology industry, and its potential to develop life-changing treatments for serious diseases makes it an attractive investment opportunity.

In conclusion, Prothena Corporation plc’s upcoming financial results announcement is highly anticipated, and investors and industry experts are eagerly waiting to see the progress of its promising pipeline. With its strong expertise, partnerships, and dedication to scientific research, Prothena is poised for continued success in the biotechnology industry.